Related Experiment Video
Updated: Jun 22, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Coronary stenting in warfarin treated patients
1Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel. dzahger@bgu.ac.il
Insights
For patients needing both coronary stents and anticoagulation, avoid drug-eluting stents when possible. A short course of triple therapy followed by aspirin and warfarin is recommended to manage dual antiplatelet therapy and anticoagulation needs.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Dual antiplatelet therapy (DAPT) is standard after coronary stent implantation.
- A subset of patients requires chronic anticoagulation, often for atrial fibrillation.
- No prospective trials guide therapy selection for this complex patient group.
Purpose of the Study:
- To review existing data on managing patients requiring both DAPT and anticoagulation.
- To provide practice recommendations for this clinical scenario.
Main Methods:
- Review of available data and literature.
- Synthesis of evidence to formulate clinical recommendations.
Main Results:
- Drug-eluting stents should be used cautiously in patients needing both DAPT and anticoagulation, particularly if not at high bleeding risk.
- A recommended regimen involves one month of triple therapy (aspirin, clopidogrel, warfarin).
Conclusions:
- Following this initial period, long-term therapy with aspirin and warfarin is suggested.
- This approach balances the need for antithrombotic protection after stenting with anticoagulation requirements.
Abstract:
Dual antiplatelet therapy is standard treatment following coronary stent implantation. An important minority of patients also require chronic anticoagulation, most commonly for atrial fibrillation. There are no prospective trials to guide the selection of therapy in this situation. In this paper we review the available data and present practice recommendations. It appears that in patients who are not at high risk of bleeding, and in whom both coronary stenting and anticoagulation are considered necessary after careful consideration, drug eluting stents should be avoided as much as possible. Triple therapy with aspirin, clopidogrel and warfarin for one month, followed by the combination of aspirin and warfarin for life is the most reasonable approach.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Acute Coronary Syndrome IV: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
